Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)
Randomized Study of Customized Adjuvant Chemotherapy based on BRCA1 mRNA Levels in Completely Resected stages II-IIIA Non-Small-Cell Lung Cancer Patients.
Non-small-cell Lung Cancer
DRUG: Docetaxel/Cisplatin control|DRUG: Docetaxel|DRUG: Gemcitabine/Cisplatin|DRUG: Docetaxel/Cisplatin
Estimated Overall Survival, To assess and compare the overall survival estimated at 5 years of both treatment groups (Control arm vs Experimental arm).

Overall survival:The proportion of participants in treatment group who are still alive for a certain period of time after inclusion., 5 years
Disease Free Survival, To assess the disease-free survival of both treatment groups. Disease-free survival: will be calculated from the date of surgery until there is some clinical evidence of disease progression or the date of death due to the disease., 5 years
Randomized, phase III, predictive pharmacogenomic, open, prospective, international, multicenter study in patients with non-small-cell lung carcinoma (NSCLC) after complete resection and with N1 or N2 involvement